Cancer/tumor profiling uses several molecular biology techniques, such as microarray, polymerase chain reaction (PCR), and in situ hybridization (ISH), to provide specific information about genetic and molecular makeup of tumor. It can detect the presence or absence of distinct disease-associated targets that guide medical practitioners in deciding the appropriate course of treatment for patients. In addition, it enables estimating individual patient risk to cancer by performing high throughput genotyping analysis of tumor DNA and predicting the reaction outcome of the therapy.
The global market is driven by increase in adoption of the cancer profiling methods by oncologists, rise in use of cancer biomarkers, surge in prevalence of cancer, and growth in demand for next-generation sequencing technique to meet the demand for cancer profiling. The global cancer/tumor profiling market was valued at $25,318 million in 2016, and is expected to reach $82,447 million by 2023, registering a CAGR of 18.4% from 2017 to 2023.
The global cancer/tumor profiling market is segmented on the basis of technology, technique, application, and region. Based on technology, it is classified into next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), microarray, and others. The in-situ hybridization segment is further categorized into fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH). Based on technique, it is divided into genomics, proteomics, epigenetics, and metabolomics. Based on application, it is classified into personalized medicine, diagnostics, biomarker discovery, prognostics, and research applications. The biomarker discovery segment generated the highest revenue in 2016, registering a CAGR of 17.4% from 2017 to 2023, and is anticipated to continue its dominance throughout the forecast period, owing to growth in demand for biomarkers. However, the personalized medicine segment is expected to witness the highest growth rate in the global market.
Geographically, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. In the recent years, Asia-Pacific has witnessed rapid growth in the global, owing to rise in incidence of cancer, and increase in demand for better healthcare services in the developing economies such as India and China. In addition, surge in the number of contract research organizations (CROs) and increase in focus of international players on the emerging markets have supplemented the market growth in Asia-Pacific region.
KEY MARKET SEGMENTS
KEY MARKET PLAYERS
The other players in the value chain include (profiles not included in the report)
Fertility Services Market by Procedure (IVF with ICSI, Surrogacy, IVF without ICSI, IUI, and Others), Service (Fresh Non-Donor, Frozen Non-Donor, Egg and Embryo Banking, Fresh Donor, and Frozen Donor), and End User (Fertility Clinics, Hospitals, Surgical Centers, and Clinical Research Institutes) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Fertility services are treatments, which aid in treating infertility in patients. In vitro fertilization (IVF), surrogacy, artificial insemination, and others are different forms of infertility services, which assists couples with infertility problems, single mothers, and the LGBT community to procreate. The global fertility services market was valued at $16,761 million ...
February 2018 | $5370 |View Details>>
Embolization Particle or embolisation refers to the passage and lodging of an embolus within the bloodstream. It may be pathological (in which sense it is also called embolism), for example a pulmonary embolism, or therapeutic, as a hemostatic treatment for bleeding or as a treatment for some types of cancer ...
February 2018 | $4880 |View Details>>
This report studies the IV Flush Syringe market. Health care professionals use IV flush syringes to clear out patients’ catheters and intravenous lines to ensure the tubes are sterile. Nurse Assist, a Texas-based medical device manufacturer, recalled all of its Normal Saline IV Flush Syringes in 2016 after ...
February 2018 | $4880 |View Details>>
Hepatocyte growth factor (HGF) (or scatter factor (SF) is a paracrine cellular growth, motility and morphogenic factor. It is secreted by mesenchymal cells and targets and acts primarily upon epithelial cells and endothelial cells, but also acts on haemopoietic progenitor cells and T cells. It has been shown to have ...
February 2018 | $3480 |View Details>>
UPCOMING MARKET RESEARCH REPORTS
2018 © Copyright Big Market Research